Smith & Nephew/$SNN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Ticker
$SNN
Sector
Primary listing
NYSE
Employees
17,000
Headquarters
Website
Smith & Nephew Metrics
BasicAdvanced
$16B
66.97
$0.56
0.62
$0.72
2.39%
Price and volume
Market cap
$16B
Beta
0.62
52-week high
$38.79
52-week low
$23.69
Average daily volume
877K
Dividend rate
$0.72
Financial strength
Current ratio
3.003
Quick ratio
1.402
Long term debt to equity
59.556
Total debt to equity
62.392
Dividend payout ratio (TTM)
66.60%
Interest coverage (TTM)
6.85%
Profitability
EBITDA (TTM)
1,436
Gross margin (TTM)
70.59%
Net profit margin (TTM)
8.26%
Operating margin (TTM)
16.60%
Effective tax rate (TTM)
19.11%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
5.81%
Return on equity (TTM)
9.14%
Valuation
Price to earnings (TTM)
66.972
Price to revenue (TTM)
5.494
Price to book
2.19
Price to tangible book (TTM)
8.28
Price to free cash flow (TTM)
40.972
Free cash flow yield (TTM)
2.44%
Free cash flow per share (TTM)
0.912
Dividend yield (TTM)
1.93%
Forward dividend yield
2.39%
Growth
Revenue change (TTM)
5.35%
Earnings per share change (TTM)
59.91%
3-year revenue growth (CAGR)
4.47%
10-year revenue growth (CAGR)
2.44%
3-year earnings per share growth (CAGR)
-0.44%
10-year earnings per share growth (CAGR)
-1.03%
3-year dividend per share growth (CAGR)
0.53%
10-year dividend per share growth (CAGR)
2.28%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Bulls say / Bears say
Smith & Nephew’s first-half trading profit surged, and a $500 million share buyback announcement pushed the stock up 15.3%, demonstrating investor confidence in the company's profit trajectory. (Reuters)
For full-year 2024, the company achieved revenue growth of 4.7% to $5.81 billion and adjusted EPS growth of 1.7% to 84.3 cents, exceeding analyst expectations and supporting guidance for 5% revenue growth and a 19–20% trading profit margin. (FT)
Operational efficiency and cost savings produced strong interim results, enabling a $500 million share buyback and fully offsetting an anticipated $15–20 million tariff hit, underscoring robust cash flow and resilience. (FT)
Setbacks in the China market due to healthcare cost controls and increased local competition have dampened growth prospects, limiting recovery in an important emerging market. (FT)
Ongoing activism and shareholder calls for a company break-up highlight continued concerns about the underperforming orthopaedics division, despite recent strategic advances. (FT)
Expected U.S. tariffs will create a $15–20 million cost headwind, threatening the company’s target for margin expansion in 2025. (FT)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Smith & Nephew News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Oct3
Smith & Nephew
DividendEx-dividend
Nov7
Smith & Nephew
DividendPayment
$0.30Per share
FAQs
What’s the current market cap for Smith & Nephew stock?
Smith & Nephew (SNN) has a market cap of $16B as of September 16, 2025.
What is the P/E ratio for Smith & Nephew stock?
The price to earnings (P/E) ratio for Smith & Nephew (SNN) stock is 66.97 as of September 16, 2025.
Does Smith & Nephew stock pay dividends?
Yes, the Smith & Nephew (SNN) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is $0.72 and the yield is 2.39%. Smith & Nephew has a payout ratio of 66.6% on a trailing twelve-month basis.
When is the next Smith & Nephew dividend payment date?
The next Smith & Nephew (SNN) dividend payment is scheduled for November 07, 2025.
What is the beta indicator for Smith & Nephew?
Smith & Nephew (SNN) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.